MAP2K1 and cancer: Of those, UO126, which is frequently used as a MAP2K1/MEK1 inhibitor but also inhibits IGF119 and EP300,20 stands out as the top candidate to test the hypothesis that stimulating autophagy through inhibition of IGF1 and EP300 could induce cell death in established cancers.